The Depo-Provera settlement update this month is registration before payment, with November 30, 2026 as the cutoff to register for the Settlement Program. Eligibility centers on prior Depo-Provera injections followed by a meningioma diagnosis, with settling parties estimating about 80% of MDL plaintiffs qualify. Depo-Provera is a birth-control shot made with medroxyprogesterone acetate.
Federal cases are centralized as MDL No. 3140, In re Depo-Provera Products Liability Litigation, before Judge M. Casey Rodgers in the Northern District of Florida. TortAdvisor, reporting Judicial Panel on Multidistrict Litigation statistics, puts pending actions at 6,412 as of October 1, 2026, in its JPML statistics summary.
Official resources:
- Read the official notice from Uscourts — Use this primary source to verify the official announcement.
- Register through Uscourts’s official page — Use this page to review requirements and register directly.
Table of Contents
- What the agreement covers now
- Who meets the basic screening test?
- Why some meningioma claims still fall outside settlement
- What to do before November 30
What the agreement covers now
Plaintiffs' leadership announced an agreement in principle with Pfizer on June 15, 2026. The deal would resolve a majority of MDL 3140 claims plus related New York meningioma claims. TortAdvisor reported the announcement in its September update.
The parties memorialized the deal on July 21-22, 2026 in a confidential Master Settlement Agreement. The court describes it as a private agreement covered by a separate confidentiality agreement. TortAdvisor summarized that structure after the court's guidance.
Who meets the basic screening test?
Wisner Baum's October 2026 update frames the basic screen in two parts in its October eligibility summary. It generally affects women with at least two injections of brand Depo-Provera, Depo-SubQ Provera 104, or generic medroxyprogesterone acetate. It also requires a later intracranial or spinal meningioma diagnosis.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
One injection alone does not meet this screen. A tumor outside the meningioma group also falls outside it. Brand and generic injections count the same for this step.
Why some meningioma claims still fall outside settlement
AboutLawsuits.com reported in November that settling parties estimate about 80% of MDL plaintiffs are eligible in its November settlement report. The same report notes that no aggregate fund, per-plaintiff amount, or payout tier has been publicly disclosed.
AboutLawsuits.com also reported that exact filing-date limits, maximum time from last injection to diagnosis, and excluded meningioma subgroups remain confidential. That confidentiality means two similar medical histories can face different outcomes. Only record-level legal review can apply those screens.
What to do before November 30
The U.S. District Court for the Northern District of Florida entered Case Management Order No. 14 on August 10, 2026, available as the case management order with exhibits. It sets November 30, 2026 as the deadline to register for the Settlement Program.
Use the remaining time to build a complete file for review. AboutLawsuits.com noted in November that non-settling cases face separate discovery deadlines. Registering preserves access to the program; missing registration closes that path. Pull pharmacy logs, visit notes, and MRI or pathology reports now so review finishes in time.
- List injection dates and product names from pharmacy and clinic records
- List meningioma diagnosis date, location, and treating doctors from imaging and pathology reports
- Send both sets for legal review well before the cutoff
You Might Also Like
- Uber Sexual Assault MDL: How Settlement Amounts Are Determined
- Monsanto Roundup Lawsuit: What the November 2026 Settlement Update Means
- Monsanto Roundup Lawsuit: Liability Theories Behind the October Settlement